BTMD
biote Corp.
BTMD offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over BTMD overall, supported by stronger fundamentals and lower modeled downside.
BTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
BTMD's revenue, profitability, cash flow and balance sheet are all currently under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BTMD PE Valuation
BTMD has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BTMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect BTMD's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BTMD on the outlook, with more favorable revenue expectations.
BTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.16 | — |
| Q3 2026 | -$0.11 | -114% |
| Q2 2026 | $0.10 | -89% |
| Q1 2026 | $0.43 | -31% |
| Q4 2025 | $0.74 | +289% |
| Q3 2025 | $0.80 | +31% |
| Q2 2025 | $0.91 | +75% |
| Q1 2025 | $0.62 | +35% |
| Q4 2024 | $0.19 | +46% |
BTMD has swung to a loss: it lost $0.11 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BTMD on earnings quality, reporting a profit while its opponent remains loss making.
BTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $43.3M | -9.6% |
| Q2 2026 | $44.2M | -9.5% |
| Q1 2026 | $44.9M | -8.3% |
| Q4 2025 | $46.4M | -6.9% |
| Q3 2025 | $48M | -6.7% |
| Q2 2025 | $48.9M | -0.6% |
| Q1 2025 | $49M | +4.7% |
| Q4 2024 | $49.8M | +9% |
BTMD's revenue has slid since its 2024 peak: $43M last quarter, down 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -12 points |
| Q2 2026 | -7.9% | -30 points |
| Q1 2026 | 7% | -13 points |
| Q4 2025 | 15% | +9.2 points |
| Q3 2025 | 17% | -6.5 points |
| Q2 2025 | 22% | +9.4 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 5.5% | -6.5 points |
BTMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -92% |
| Q2 2026 | -$3.7M | -171% |
| Q1 2026 | $3.5M | -27% |
| Q4 2025 | $6.5M | -39% |
| Q3 2025 | $13.6M | -3.1% |
| Q2 2025 | $5.3M | -29% |
| Q1 2025 | $4.8M | -27% |
| Q4 2024 | $10.7M | +50% |
BTMD still generates free cash flow, though less than at its 2024 peak: $7M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BTMD on cash flow, with more consistent year-over-year improvement.
BTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.2% | -1.2M shares |
| 1 year | -25% | -9.3M shares |
| 3 years | -12% | -3.6M shares |
BTMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.4M |
| Q2 2026 | $4.8M |
| Q1 2026 | $1.1M |
| Q4 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.5M |
| Q1 2024 | $4.1M |
BTMD spent $7M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.6x | High |
| Q2 2026 | 5.9x | High |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
BTMD's net debt is about 8.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BTMD on leverage, with a lower net debt burden relative to earnings.
BTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 6.0 | Oversold |
BTMD's weekly RSI is 32 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BTMD PE vs Healthcare Sector
| Metric | BTMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
| PE % | 73 | 36 | 37 pts above |
BTMD has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 7.2% below |
| 20 week MA | $1.54 | 33% below |
| 50 week MA | $1.89 | 46% below |
| 100 week MA | $2.87 | 64% below |
| 200 week MA | $4.28 | 76% below |
BTMD is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BTMD on trend strength, trading above more of its moving averages.
BTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.85 | -2% |
| 2022 | $9.85 | $3.91 | -60% |
| 2023 | $3.91 | $4.94 | +26% |
| 2024 | $4.94 | $5.99 | +21% |
| 2025 | $5.99 | $2.68 | -55% |
| 2026 YTD | $2.68 | $1.03 | -62% |
BTMD has finished lower in three of the last five years. It's down 62% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BTMD on returns for 2026, with the stronger performance.